MedPub Date : 2026-11-13Epub Date: 2026-10-30DOI: 10.1016/j.medj.2026.101336
Jose A Santiago, Olivier Rascol, Tom Foltynie, Wassilios G Meissner, Judith A Potashkin, Jean C Gutierrez-Silva, Mohammad Nafeli Shahrestani, Yusen Wu, Tatjana Rundek, Ihtsham Ul Haq
{"title":"Metabolic endotyping for mechanism-informed Alzheimer's and Parkinson's disease trials.","authors":"Jose A Santiago, Olivier Rascol, Tom Foltynie, Wassilios G Meissner, Judith A Potashkin, Jean C Gutierrez-Silva, Mohammad Nafeli Shahrestani, Yusen Wu, Tatjana Rundek, Ihtsham Ul Haq","doi":"10.1016/j.medj.2026.101336","DOIUrl":"10.1016/j.medj.2026.101336","url":null,"abstract":"<p><p>Metabolically targeted therapies for Alzheimer's disease and Parkinson's disease have yielded mixed results despite convergent evidence implicating three interconnected axes of metabolic dysfunction: insulin signaling, cellular bioenergetics, and lipid-lysosomal biology. We argue that this pattern partly reflects a trial-design problem: therapeutics such as glucagon-like peptide 1 receptor agonists, terazosin, and stearoyl-CoA desaturase inhibitors generally have been tested in biologically unselected populations, with endpoints often distal to the targeted mechanism. We propose as a testable hypothesis that a metabolic endotype-a measurable, biomarker-supported pattern of metabolic dysfunction-spans subsets of both diseases and that failure to enrich for this endotype could dilute therapeutic signals in all-comer trials. We outline a modular four-tier framework integrating prodromal risk, metabolic vulnerability, pathway-specific confirmation, and mechanistic deep phenotyping to make Alzheimer's and Parkinson's disease trials more interpretable and therapeutically informative.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101336"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13733349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MedPub Date : 2026-11-13DOI: 10.1016/j.medj.2026.101332
Tommaso Clemente, Antonella Castagna
{"title":"Once-weekly oral islatravir/lenacapavir: Closer to clinical practice?","authors":"Tommaso Clemente, Antonella Castagna","doi":"10.1016/j.medj.2026.101332","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101332","url":null,"abstract":"<p><p>The phase 3 ISLEND-1<sup>1</sup> and ISLEND-2<sup>2</sup> trials show that once-weekly oral islatravir (ISL)/lenacapavir (LEN) is non-inferior to contemporary daily antiretroviral therapy (ART) for maintaining virological suppression at 48 weeks. In ISLEND-2, adherence and treatment satisfaction were high, while safety findings across both trials were broadly reassuring. Despite important remaining uncertainties, these findings make weekly oral ART clinically credible.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":"7 11","pages":"101332"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MedPub Date : 2026-11-13Epub Date: 2026-09-18DOI: 10.1016/j.medj.2026.101296
Victoria Yuan, Hirotaka Ieki, Alexander Sandhu, Long H Nguyen, Paul P Cheng, Stephanie T Chang, Andrew P Ambrosy, Alan C Kwan, Alan S Go, Susan Cheng, David Ouyang
{"title":"Deep learning-enabled screening of chronic kidney disease from echocardiography.","authors":"Victoria Yuan, Hirotaka Ieki, Alexander Sandhu, Long H Nguyen, Paul P Cheng, Stephanie T Chang, Andrew P Ambrosy, Alan C Kwan, Alan S Go, Susan Cheng, David Ouyang","doi":"10.1016/j.medj.2026.101296","DOIUrl":"10.1016/j.medj.2026.101296","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) affects nearly 850 million individuals globally. The prevalence of undiagnosed CKD is over 60%.</p><p><strong>Methods: </strong>Taking advantage of the relationship between CKD and cardiovascular disease, we developed a deep learning (DL) model to detect CKD from parasternal long-axis (PLAX) videos, using 325,377 PLAX videos from 62,818 patients at Cedars-Sinai Medical Center (CSMC). We externally validated our model in two independent cohorts of 2,762 patients at Stanford Healthcare (SHC) and 41,611 patients at Kaiser-Permanente Northern California (KPNC).</p><p><strong>Findings: </strong>In a held-out test cohort at CSMC, our model detected any stage of CKD with an area under the curve (AUC) of 0.756 (95% confidence interval: 0.749-0.763), with consistently strong performance in the KPNC (AUC: 0.718 [0.714-0.723]) and SHC (AUC: 0.719 [0.704-0.735]) cohorts. Our model performed well across subgroups with and without metabolic comorbidities, suggesting that it learned imaging features specific to CKD.</p><p><strong>Conclusions: </strong>Our DL echo model detected CKD with robust performance at two external clinical sites, thus offering an avenue for noninvasive screening and improved detection rates.</p><p><strong>Funding: </strong>This work was supported by the Sarnoff Cardiovascular Research Foundation, the American Heart Association (25POST1357984 and 25AHAI1487693), and the National Institutes of Health (R00HL157421, R01HL173487, and R01HL173526).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101296"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MedPub Date : 2026-11-13Epub Date: 2026-10-14DOI: 10.1016/j.medj.2026.101327
Hannah S Fuchs, Phil Xie, Sabrina A James, Zheyi Cao, Thomas M Carroll, Masato Inoue, Paulina Siejka-Zielińska, Sungyong Kim, Brittany-Amber Jacobs, Emelie Shepherd, Ethan Wang, Joseph A Chadwick, Bob Amess, Duncan Parkes, Simon R Lord, Somnath Mukherjee, Tim Underwood, Ioannis Karydis, Russell Petty, Lucinda Griffiths, Katy J McCann, Sam Wilding, Gareth Griffiths, Cleopatra Pike, Megan Lawrence, Daniel R McGowan, Kevin M Bradley, Skirmantas Kriaucionis, Chun-Xiao Song, Richard P Owen, Benjamin Schuster-Boeckler, Mark R Middleton, Xin Lu
{"title":"Tumor DNA methylation subtypes and expression levels of CFISH predict response and overall survival to immunochemotherapy.","authors":"Hannah S Fuchs, Phil Xie, Sabrina A James, Zheyi Cao, Thomas M Carroll, Masato Inoue, Paulina Siejka-Zielińska, Sungyong Kim, Brittany-Amber Jacobs, Emelie Shepherd, Ethan Wang, Joseph A Chadwick, Bob Amess, Duncan Parkes, Simon R Lord, Somnath Mukherjee, Tim Underwood, Ioannis Karydis, Russell Petty, Lucinda Griffiths, Katy J McCann, Sam Wilding, Gareth Griffiths, Cleopatra Pike, Megan Lawrence, Daniel R McGowan, Kevin M Bradley, Skirmantas Kriaucionis, Chun-Xiao Song, Richard P Owen, Benjamin Schuster-Boeckler, Mark R Middleton, Xin Lu","doi":"10.1016/j.medj.2026.101327","DOIUrl":"10.1016/j.medj.2026.101327","url":null,"abstract":"<p><strong>Background: </strong>Predicting patient response to immunochemotherapy is vital but challenging and poorly studied in the (neo)adjuvant setting. We showed that tumor monocyte content (TMC) predicts overall survival of advanced esophageal cancer (OC) in response to immunochemotherapy. We report clinical outcomes of 35 operable OC patients receiving ICI-based therapy and molecular profiling of the unique phase-2 LUD2015-005 trial treating 73 OC patients (38 advanced/inoperable and 35 operable) in the (neo)adjuvant setting.</p><p><strong>Methods: </strong>LUD2015-005 trial patients were treated with 4-week immune checkpoint inhibitor (ICI)-only before combination with standard of care. Paired and longitudinally collected biopsies of tumor and multiple adjacent normal sites were bi-dissected to extract DNA and RNA. Whole-genome, methylome, single-cell and bulk RNA sequencing data generated from the entire LUD2015-005 cohort were used for cell-deconvolution and data integration analysis.</p><p><strong>Findings: </strong>Neoadjuvant ICI-based combination therapy of operable OC in the LUD2015-005 trial revealed improved overall outcomes. Tumor monocytes contribute to tumor immune microenvironment (TiME) remodeling and associate with tumor reactive CD8<sup>+</sup> T cells upon ICI+ chemotherapy/chemoradiotherapy. We identified five DNA-methylation subtypes with distinct TiME and a TMC-related five-gene signature CFISH (CXCL8, FCN1, IFI30, SLC11A1, and HLA-DRA) as highly predictive biomarkers of overall survival in OC and beyond.</p><p><strong>Conclusions: </strong>These findings highlight the importance of the myeloid compartment in ICI response and the potential of CFISH and tumor DNA methylation in patient stratification for immunochemotherapy.</p><p><strong>Funding: </strong>This work is mainly funded by Ludwig Institute for Cancer Research, CRUK Grants A21998 and C30423/A2541, and NIHR Oxford Biomedical Research Center. AstraZeneca UK Limited provided durvalumab and tremelimumab for LUD2015-005.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101327"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MedPub Date : 2026-11-13Epub Date: 2026-10-13DOI: 10.1016/j.medj.2026.101326
Nick A Kuburich, Mohamed A Gouda, Breanna R Demestichas, Preetesh Jain, Petra den Hollander, Evgeny Yakirevich, Razelle Kurzrock, Wafik S El-Deiry, Sendurai A Mani, Vivek Subbiah
{"title":"Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncology.","authors":"Nick A Kuburich, Mohamed A Gouda, Breanna R Demestichas, Preetesh Jain, Petra den Hollander, Evgeny Yakirevich, Razelle Kurzrock, Wafik S El-Deiry, Sendurai A Mani, Vivek Subbiah","doi":"10.1016/j.medj.2026.101326","DOIUrl":"10.1016/j.medj.2026.101326","url":null,"abstract":"<p><p>The advent of precision oncology has brought substantial advancements in cancer therapy, yet it has been accompanied by equally complex resistance mechanisms. Among these mechanisms, histological transformations can compromise the effectiveness of targeted therapies, resulting in a loss of clinical benefit following initial success. Understanding these evolutionary processes is crucial for developing the next generation of cancer treatments that can effectively combat resistance. This review examines histological transformation as a key mechanism of resistance to anticancer therapies, driven by various forms of tumor plasticity, and explores into the underlying processes and mechanisms that drive these changes. We also discuss how precision oncology and an appreciation of cancer plasticity can be leveraged to overcome histological transformation and lead to improved patient outcomes.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101326"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MedPub Date : 2026-11-13DOI: 10.1016/j.medj.2026.101333
Qian Da, Yijiang Chen, Min Ju, Zheyi Ji, Albert Zhou, Wenwen Wang, Matthew A Abikenari, Philip Chikontwe, Guillaume Larghero, Bowen Chen, Peter Neidlinger, Dingrong Zhong, Shuhao Wang, Wei Xu, Drew Williamson, German Corredor, Sen Yang, Le Lu, Xiao Han, Kun-Hsing Yu, Junzhou Huang, Xiyue Wang, Laura Barisoni, Geert Litjens, Anant Madabhushi, Lifeng Zhu, Chaofu Wang, Junhan Zhao, Weiguo Hu
{"title":"Clinical readiness of foundation and agentic AI in computational pathology.","authors":"Qian Da, Yijiang Chen, Min Ju, Zheyi Ji, Albert Zhou, Wenwen Wang, Matthew A Abikenari, Philip Chikontwe, Guillaume Larghero, Bowen Chen, Peter Neidlinger, Dingrong Zhong, Shuhao Wang, Wei Xu, Drew Williamson, German Corredor, Sen Yang, Le Lu, Xiao Han, Kun-Hsing Yu, Junzhou Huang, Xiyue Wang, Laura Barisoni, Geert Litjens, Anant Madabhushi, Lifeng Zhu, Chaofu Wang, Junhan Zhao, Weiguo Hu","doi":"10.1016/j.medj.2026.101333","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101333","url":null,"abstract":"<p><p>Foundation and agentic AI show great promise for computational pathology, with clinical readiness now widely anticipated. We define readiness at the intended-use system level; outline requirements for evidence, validation, economic sustainability, and governance; and propose a roadmap toward responsible deployment.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":"7 11","pages":"101333"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MedPub Date : 2026-11-13Epub Date: 2026-09-18DOI: 10.1016/j.medj.2026.101298
Ming Shao, Yiteng Lu, Wenjie Xie, Annan Lu, Yutong Jiang, Xiaojing Chen, Yu Chai, Qihua Le, Lijia Tian, Yongyun Li, Jini Qiu, Kun Shan, Chenya Wang, Jiaxu Hong, Zhuang Liu
{"title":"Mucoadhesive recombinant human catalase for dry eye disease: From protein engineering to first-in-human study.","authors":"Ming Shao, Yiteng Lu, Wenjie Xie, Annan Lu, Yutong Jiang, Xiaojing Chen, Yu Chai, Qihua Le, Lijia Tian, Yongyun Li, Jini Qiu, Kun Shan, Chenya Wang, Jiaxu Hong, Zhuang Liu","doi":"10.1016/j.medj.2026.101298","DOIUrl":"10.1016/j.medj.2026.101298","url":null,"abstract":"<p><strong>Background: </strong>Oxidative stress caused by excess reactive oxygen species (ROS) plays a key role in the progression of dry eye disease (DED), yet no approved DED therapy directly eliminates ROS. Here, we develop an antioxidant biologic with enhanced ocular-surface retention by thiol engineering of recombinant human catalase (hCAT) as a new ROS-scavenging eye drop therapy for DED.</p><p><strong>Methods: </strong>Thiolated hCAT (hCAT-SH) was characterized for activity, stability, mucin interaction, and ocular retention. Efficacy, mechanism, and safety were evaluated in mouse, rabbit, and rat studies, followed by a randomized, double-blind, placebo-controlled first-in-human trial in 30 patients with DED.</p><p><strong>Findings: </strong>With formulation optimization, hCAT-SH maintained enzymatic activity and formulation stability, while exhibiting enhanced mucin binding and prolonged corneal retention. In mouse DED models, hCAT-SH reduced oxidative stress, accelerated epithelial repair, restored tear secretion, and modulated inflammatory and barrier-repair pathways distinct from cyclosporine. In rabbits, exposure remained predominantly ocular with favorable repeated-dose tolerability. Clinically, 0.1 mg/mL hCAT-SH significantly improved corneal fluorescein staining, reduced tear cytokine levels and corneal dendritic cell density versus placebo, and raised no treatment-related safety concerns.</p><p><strong>Conclusions: </strong>hCAT-SH is a carrier-free, long-retained H<sub>2</sub>O<sub>2</sub>-scavenging biologic, with integrated preclinical and first-in-human evidence supporting further development as a new DED drug.</p><p><strong>Funding: </strong>National Natural Science Foundation of China; National Technology Innovation Center for Biopharmaceuticals; Jiangsu Key R&D Program; National Key R&D Program of China; Shanghai \"Dawn\" Program; Shanghai Science and Technology Innovation Action Plans; Shanghai Municipal Commission of Health; Shanghai High-Quality Development Plan for Science and Technology Industry; and Macao FDCT.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101298"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Endovascular treatment for ischemic stroke due to distal medium vessel occlusions: A nationwide multicenter registry.","authors":"Changwei Guo, Jiaxing Song, Zhenxuan Tian, Chengsong Yue, Gaoming Li, Wenzhe Sun, Boyu Chen, Chong Zheng, Guoyong Zeng, Shengli Chen, Chen Gong, Xiaolei Shi, Lilan Wang, Shihai Yang, Zhongjun Chen, Xiangping Cheng, Changchun Jiang, Shuyu Jiang, Haoxuan Zhu, Jie Yang, Guojian Liu, Miao Chai, Jifei Liu, Hetai Lai, Li Wang, Quanlong Hong, Yong Liu, Weidong Huang, Mengxiu Li, Min Zhang, Weishi Chen, Peiyang Zhou, Jincheng Liu, Yuanjun Shan, Shunfu Jiang, Dahong Yang, Xu Xu, Jinfu Ma, Linyu Li, Jie Tang, Zhaoyun Guo, Shuchun Huang, Jian Wang, Zhibin Ai, Tao Xu, Liping Huang, Zhaoxia Yang, Wei Ma, Nizhen Yu, Xin Zou, Jun Luo, Xiaolin Tan, Youlin Wu, Zhuang Li, Zhouzhou Peng, Kunxin Lin, Xuanyu Chen, Linshan Wu, Linyu Zhang, Kun Luo, Yanjie Huang, Xuan Zhou, Hui Liu, Jun Wen, Hao Tang, Hanming Tu, Zhenchang Zhang, Yaoyu Tian, Jian Shen, Maojun Jiang, Yongtao Guo, Guoping Ma, Duolao Wang, Thanh Nguyen, Raul Nogueira, Mayank Goyal, Jeffrey Saver, Wenjie Zi, Chang Liu","doi":"10.1016/j.medj.2026.101328","DOIUrl":"10.1016/j.medj.2026.101328","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness and safety of endovascular treatment (EVT) for acute ischemic stroke attributable to distal medium vessel occlusion (DMVO) remain uncertain. This study aimed to compare the effectiveness and safety of EVT plus standard medical treatment (SMT) versus SMT alone in patients with DMVO.</p><p><strong>Methods: </strong>This nationwide multicenter registry included patients with DMVO presenting within 24 h of last known well at 116 sites in China between 2023 and 2025. The primary outcome was freedom from disability (modified Rankin Scale score of 0-1) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH) within 48 h and 90-day mortality. The primary analysis was conducted using inverse probability of treatment weighting.</p><p><strong>Findings: </strong>Among 2,524 patients, 1,564 received EVT plus SMT, and 960 received SMT alone. EVT plus SMT was associated with a higher rate of freedom from disability at 90 days compared with SMT alone (adjusted risk ratio [aRR], 1.15; 95% confidence interval [CI], 1.02-1.29; adjusted risk difference, 4.36%; 95% CI, 1.73%-6.99%). However, EVT plus SMT was associated with an increased risk of sICH (aRR, 4.03; 95% CI, 2.46-6.59). Mortality at 90 days did not differ significantly between the groups (aRR, 0.97; 95% CI, 0.81-1.16).</p><p><strong>Conclusions: </strong>In patients with DMVO, EVT plus SMT was associated with a modestly higher rate of freedom from disability at 90 days but an increased risk of sICH.</p><p><strong>Funding: </strong>National Natural Science Foundation of China (82425021, 82571498, and 82271349), Natural Science Foundation of Chongqing (CSTB2024NSCQ-MSX0359 and CSTB2024NSCQ-KJFZMSX0063), and Chongqing Technology Innovation and Application Development Project (CSTB2022TIAD-KPX0160).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101328"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MedPub Date : 2026-11-13Epub Date: 2026-09-16DOI: 10.1016/j.medj.2026.101297
Cho-Yi Huang, David Seong, Jonathan Reiss, Chi-Hung Shu, Mohammad Amin Sadeghi, Philip Chung, Liu K Yang, Lei Xue, Yaxin Fang, Rui Xu, Xiruo Ding, Saber Sheybani, Lichy Han, Bernard C Mawuli, Marc Ghanem, Mehrdad Kiamari, Alan L Chang, Tomin James, Samson J Mataraso, Camilo Espinosa, Eloise Berson, Po-Nien Tsao, Martin S Angst, Brice Gaudiliere, Lawrence Prince, Gary Shaw, David Stevenson, Nima Aghaeepour
{"title":"An adult proteomic signature associated with very low birth weight and chronic disease risk.","authors":"Cho-Yi Huang, David Seong, Jonathan Reiss, Chi-Hung Shu, Mohammad Amin Sadeghi, Philip Chung, Liu K Yang, Lei Xue, Yaxin Fang, Rui Xu, Xiruo Ding, Saber Sheybani, Lichy Han, Bernard C Mawuli, Marc Ghanem, Mehrdad Kiamari, Alan L Chang, Tomin James, Samson J Mataraso, Camilo Espinosa, Eloise Berson, Po-Nien Tsao, Martin S Angst, Brice Gaudiliere, Lawrence Prince, Gary Shaw, David Stevenson, Nima Aghaeepour","doi":"10.1016/j.medj.2026.101297","DOIUrl":"10.1016/j.medj.2026.101297","url":null,"abstract":"<p><strong>Background: </strong>Adults born at very low birth weight (VLBW, <1.5 kg) have elevated risks of chronic disease, but it is unclear whether adult plasma proteomics contains a detectable signature associated with recalled VLBW.</p><p><strong>Methods: </strong>We analyzed 2,923 plasma proteins in 26,061 UK Biobank participants (median sampling age 56.4 years) with recalled birth weight, including 368 with VLBW and 25,693 with normal birth weight. We derived a machine learning proteomic prematurity index (PPI) distinguishing these groups and evaluated associations with 425 adult diagnoses, discrimination relative to birth weight and electronic health record (EHR) information, incident diseases after proteomic sampling, and exploratory biological interpretation.</p><p><strong>Findings: </strong>The PPI was associated with recalled VLBW (odds ratio [OR], 7.32; 95% confidence interval [95% CI], 4.01-13.42) and remained independently associated after adjustment for EHR-derived VLBW probability (OR, 5.82; 95% CI, 3.99-8.47). Recalled VLBW was associated with adult disease burden, and PPI showed higher discrimination than birth weight for 370 of 425 diseases. Incident-only analyses preserved the cross-disease hazard ratio patterns, while fewer events and adult factor adjustment attenuated some associations. Exploratory biological annotations paralleled the disease patterns. Among participants with normal birth weight, higher PPI was associated with disease burden and subsequent disease risk, indicating that PPI is not VLBW specific.</p><p><strong>Conclusions: </strong>Adult plasma proteomics identifies a signature associated with recalled VLBW that provides information about adult disease risk beyond birth weight and EHR-derived measures. These findings are hypothesis generating and do not establish a direct molecular consequence of prematurity. External validation is required before clinical application.</p><p><strong>Funding: </strong>The March of Dimes, the Alfred E. Mann Foundation, the Universe of Mind, and the Bill & Melinda Gates Foundation (INV-037517 and INV-076306).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101297"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MedPub Date : 2026-11-13Epub Date: 2026-10-13DOI: 10.1016/j.medj.2026.101325
Xingyun Yao, Haobo Sun, Cheng Fang, Qingqu Guo, Jun Wang, Guofeng Chen, Songzhao Zhang, Baozhong Li, Yanwu Jin, Ganshu Xia, Zhiqiang Liu, Fei Meng, Jie Jin, Xiaofei Gao, Yuehua Han
{"title":"Early detection of gastric cancer using DNA features in red blood cells, with multicenter validation.","authors":"Xingyun Yao, Haobo Sun, Cheng Fang, Qingqu Guo, Jun Wang, Guofeng Chen, Songzhao Zhang, Baozhong Li, Yanwu Jin, Ganshu Xia, Zhiqiang Liu, Fei Meng, Jie Jin, Xiaofei Gao, Yuehua Han","doi":"10.1016/j.medj.2026.101325","DOIUrl":"10.1016/j.medj.2026.101325","url":null,"abstract":"<p><strong>Background: </strong>Early detection of gastric cancer (GC) is limited by invasive endoscopy and poor sensitivity of blood-based biomarkers. Red blood cells (RBCs), the most abundant cells in the circulation, are anucleate but can retain DNA remnants that have been associated with pathological stress. Here, we report a non-invasive strategy for GC detection based on genome-wide profiling of DNA remnants retained in RBCs (rbcDNA).</p><p><strong>Methods: </strong>We performed shallow whole-genome sequencing of rbcDNA from 1-2 mL of peripheral blood of 865 individuals, including 434 treatment-naive GC patients and 431 non-GC controls with benign gastric conditions. In the discovery cohort, we identified 1,000 reproducible rbcDNA read-depth features distinguishing GC from non-cancer states. A machine learning classifier based on dimensionally reduced GC-associated rbcDNA features was trained in the discovery cohort (n = 435), with the cutoff fixed at 90% specificity, and evaluated in a test cohort (n = 109) and three independent multicenter validation cohorts (n = 321).</p><p><strong>Findings: </strong>The classifier achieved the areas under the receiver operating characteristic curve (AUCs) of 84% in nested cross-validation of the discovery cohort and 95% in the test cohort. Across three hospital-based multicenter validation cohorts, performance remained consistent, with 83%-90% overall sensitivity and 82%-89% sensitivity for stage I GC. Additionally, the classifier distinguished early-stage GC from precancerous lesions and other tumors and detected ∼80% of GC cases negative for tumor markers.</p><p><strong>Conclusions: </strong>These findings demonstrate the potential of rbcDNA as a non-invasive biomarker for early-stage GC detection.</p><p><strong>Funding: </strong>This work was supported by the Key Research and Development Program of Zhejiang Province (2026C02A1176 and 2024C03170).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101325"},"PeriodicalIF":13.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}